To establish diagnostic criteria for acute-on-chronic liver failure (ACLF) in Japan, the Intractable Hepato-Biliary Disease Study Group of Japan undertook a multicenter pilot survey for patients fulfilling the Asian Pacific Association for the Study of the Liver (APASL), Association for the Study of the Liver-Chronic Liver Failure (EASL-Clif) Consortium, or Chinese Medical Association (CMA) diagnostic criteria for ACLF. The APASL criteria were suitable for screening Japanese patients with ACLF when patients whose conditions were triggered by gastrointestinal bleeding were included within the disease entity, and the EASL-Clif Consortium criteria were useful for classifying the severity of the patients' conditions. Based on these observations, the Study Group proposed the following diagnostic criteria for ACLF in Japan: patients with cirrhosis and a ChildPugh score of 5-9 should be diagnosed as having ACLF when a deterioration of liver function (serum bilirubin level ≥5.0 mg/dL and prothrombin time value ≤40% of the standardized values and/or international normalization rate ≥1.5) caused by severe liver damage develops within 28 days after acute insults, such as alcohol abuse, bacterial infection, gastrointestinal bleeding, or the exacerbation of underlying liver diseases. The severities of the patients can be classified into four grades depending on the extent of the deterioration in organ functions, including kidney, cerebral, blood coagulation, circulatory and respiratory functions, as well as liver function. The usefulness of these novel criteria should be validated prospectively in a large-scale cohort in the future.
INTRODUCTION
L IVER FAILURE IS a disease entity characterized by icterus, ascites, blood coagulation disorders, and hepatic encephalopathy developing as a consequence of a decreased number and/or the deteriorated function of hepatocytes. Liver failure is classified into three types depending on the duration between disease onset and the occurrence of liver failure symptoms: acute liver failure for <8 weeks, late-onset hepatic failure for 8-24 weeks, and chronic liver failure for >24 weeks. Chronic liver failure develops mainly in patients with decompensated cirrhosis in whom various symptoms occur as a consequence of portal hypertension as well as liver failure. In general, both liver failure and portal hypertension progress irreversibly in these patients unless the causes of the liver damage are removed through antiviral therapies for patients with hepatitis B virus (HBV)-induced and hepatitis C virus (HCV)-induced liver injuries, abstinence for patients with alcoholic liver injuries, or glucocorticoid therapy for patients with autoimmune hepatitis. In some patients with cirrhosis, however, liver function deteriorates rapidly following acute insults such as alcohol abuse, bacterial infection (including spontaneous bacterial peritonitis [SBP]), or gastrointestinal bleeding. Liver function can also deteriorate rapidly after the spontaneous exacerbation of hepatitis, especially in patients with cirrhosis caused by HBV infection or autoimmune hepatitis, as well as after the administration or withdrawal of immunosuppressive agents. Such liver Nonefailure is called acute-on-chronic liver failure (ACLF) to distinguish it from chronic decompensation of cirrhosis. 1 Previously, the Subcommittee for Fulminant Hepatitis (Chairman: Professor Satoshi Mochida, Saitama Medical University, Saitama, Japan) within the Intractable Hepato-Biliary Disease Study Group of Japan, sponsored by the Ministry of Health, Labour and Welfare (Researcher-in-Chief: Professor Hirohito Tsubouchi, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan), established diagnostic criteria for acute liver failure in Japan 2,3 and the classification criteria for the etiologies of acute liver failure. 4, 5 In Japan, however, the diagnostic criteria for ACLF have not yet been established, and the epidemiological and clinical features of patients with ACLF are unclear. In contrast, in Asia as well as in Europe and the USA, ACLF has received much attention. The Asian Pacific Association for the Study of the Liver (APASL) proposed diagnostic criteria for ACLF in 2009 6 and published a position paper on the management of patients with ACLF in 2014. 7 In Europe and the USA, the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Disease unified the concept of ACLF in 2012, 1, 8 and the EASL-Chronic Liver Failure (Clif) Consortium carried out a multicenter survey of patients: the EASL-Clif AcuteOn-Chronic Liver Failure in Cirrhosis (CANONIC) study. Based on the results of this survey, EASL published a summary of the demographic and clinical features and the outcomes of patients with ACLF in 2013. 9 In addition, the Chinese Medical Association (CMA) published a guideline for the diagnosis and treatment of ACLF in 2012. 10 The demographic and clinical features of patients with cirrhosis differ between Japan and other countries. The most common causative events for underlying liver disease in patients with ACLF are alcohol abuse in Europe and the USA 9 and persistent HBV infection in Asian countries. 10 In contrast, in Japan, the most common etiology of cirrhosis was reported to be HCV infection (60.9% in a study of 33 379 patients enrolled in a nationwide survey), whereas HBV infection and alcohol abuse were causative agents in only 13.9% and 13.6% of patients with cirrhosis, respectively. 11 Considering these discrepancies in the etiologies of cirrhosis between Japan and other countries, the Subcommittee for Fulminant Hepatitis (Chairman: Professor Satoshi Mochida) in the Intractable HepatoBiliary Disease Study Group of Japan (Researcher-in-Chief: Professor Hajime Takikawa, Teikyo University, Tokyo, Japan) undertook a multicenter pilot survey of patients with ACLF between 2015 and 2016. 12 In this survey, patients fulfilling the diagnostic criteria for ACLF according to the APASL, EASL-Clif Consortium, or CMA criteria were enrolled; it was found that the APASL criteria were suitable for screening Japanese patients with ACLF, and the EASL-Clif Consortium criteria were useful for classifying the severity of the patients' conditions. Based on these observations, the diagnostic criteria for ACLF in Japan were determined as shown in Table 1 .
DISCUSSION
T HE ABOVE CRITERIA were determined through discussions among members of the Subcommittee for Fulminant Hepatitis in the Intractable Hepato-biliary Diseases Study Group of Japan, and the minutes of the proceedings are presented here in the form of a series of questions and answers, as follows.
How should we determine the standards for diagnosing liver failure?
According to the APASL criteria, 7 patients with chronic liver disease were diagnosed as having ACLF when an acute hepatic insult manifesting as jaundice and coagulopathy led to the development of complications such as clinical ascites and/or hepatic encephalopathy within 4 weeks. In these criteria, jaundice was defined as a serum bilirubin level ≥5.0 mg/dL, whereas coagulopathy was defined as a prothrombin time INR ≥1.5 and/or an activity <40% of the control value. One hundred and twelve patients were enrolled in the pilot survey; 109 patients (97.3%) fulfilled the APASL criteria for decompensation, and 53 patients (47.3%) and 54 patients (48.2%) fulfilled the EASL-Clif Consortium criteria and the CMA criteria, respectively. Only three patients and one patient were excluded from the disease entity of ACLF as defined by the APASL criteria despite fulfilling the EASL-Clif Consortium criteria and the CMA criteria, respectively. Thus, the APASL criteria are superior to the EASL-Clif Consortium criteria and the CMA criteria for screening Japanese patients with cirrhosis who manifest a rapid deterioration of liver function. The survival rate of patients treated without liver transplantation (LT) was 47.2% among those fulfilling the APASL criteria, and it was 35.8% and 44.4% among those fulfilling the EASL-Clif Consortium criteria and the CMA criteria, respectively. Thus, the APASL criteria merit consideration for including patients with both favorable and unfavorable outcomes. Although patients with ACLF have "a prothrombin time INR of 1.5 or more and/or an activity less than 40% of the control value" according to the APASL criteria, the standard prothrombin time was modified as "prothrombin time values of 40% or less of the control value and/or an INR of 1.5 or more" for consistency with the diagnostic criteria for acute liver failure in Japan. 2, 3 In contrast, the standard for the serum bilirubin level was not stated in the diagnostic criteria for acute liver failure in Japan. 2, 3 Serum bilirubin level, however, was included as a factor in outcome prediction models for patients with acute liver failure; the split values for serum bilirubin levels were 10 mg/dL and 15.0 mg/dL in the scoring model, 13 and the first split value of the decision tree was set as 17.9 mg/dL in the data-mining model. 14 Both of these values were higher than the standard in the criteria for ACLF. As chronic liver diseases with the potential to aggravate liver dysfunction are present as underlying conditions in patients with ACLF, but not in patients with acute liver failure, some discrepancies in the standards for the two diseases seem reasonable. Moreover, in Japan, the extent of liver dysfunction in patients with decompensated cirrhosis defined by the Act for the Welfare of Persons with Physical Disabilities (Act No. 283 of 1949) is determined based on a serum bilirubin level in a split value of 5.0 mg/dL as a supplementary item, while the grading is mainly based on the Child-Pugh scores. Thus, Japanese hepatologists are likely to adapt to the use of serum bilirubin level standards in the novel diagnostic criteria for ACLF. Of note, neither the prothrombin time nor the serum bilirubin level reflect the severity of patients with cholestatic cirrhosis, such as cirrhosis caused by primary biliary cholangitis (PBC) or primary sclerosing cholangitis, as the prothrombin time can be altered by vitamin K malabsorption. In such patients, the diagnostic criteria for ACLF should be applied following supplementation with vitamin K agents.
Although clinical ascites and hepatic encephalopathy were included in the APASL criteria, both symptoms were excluded from the diagnostic criteria for ACLF in Japan. The presence of ascites can be determined conveniently using ultrasound imaging even if the amount of ascites is relatively small. Thus, the definition of clinical ascites is ambiguous. According to the detailed enforced regulations for liver dysfunction defined by the Act for the Welfare of Persons with Physical Disabilities (Act No. 283 of 1949), the presence of <1 L of ascites is scored as 1 point in the Child-Pugh classification, and such ascites are excluded from clinical ascites. The introduction of this standard, however, could lead to confusion in Japan. Moreover, hepatic encephalopathy was excluded from the present criteria, as cerebral function failure defined by the extent of hepatic encephalopathy is a factor included in the EASL-Clif Consortium criteria, and we decided to use these criteria to grade the severity of ACLF.
Should patients with non-cirrhosis as well as those with cirrhosis at baseline be included in the disease entity of ACLF?
According to the APASL criteria, patients with previously diagnosed or undiagnosed chronic liver disease, including those with non-cirrhotic liver diseases, were included in the disease entity of ACLF, 7 whereas only patients with cirrhosis were diagnosed as having ACLF based on the EASL-Clif Consortium criteria. 9 These discrepancies may reflect the difference in etiologies of ACLF among patients in Asian countries and those in Europe and the USA: the exacerbation of hepatitis because of HBV infection is common in the former countries, whereas alcoholic hepatitis is common in the latter. Among the 109 Japanese patients who met the criteria for decompensation by APASL in the pilot survey, cirrhosis was not an underlying condition in 25 patients (22.9%) at baseline. 12 Thus, patients without cirrhosis were not rare among those who met the APASL criteria in Japan. Among the patients with ACLF who met the APASL criteria, however, the most frequent etiology for underlying liver disease was alcohol abuse, 12 suggesting that the clinical features of patients in Japan may be similar to those in Europe and the USA, but not to those in Asian countries. Moreover, patients with cirrhosis at the baseline of the exacerbation of their liver injury are excluded from the disease entity of acute liver failure in Japan, whereas those with non-cirrhotic liver diseases can be diagnosed as having acute liver failure when liver dysfunction characterized by a prothrombin time INR ≥1.5 and/or an activity of ≤40%of the control value develops within 8 weeks of disease onset. 2, 3 For consistency with the diagnostic criteria for acute liver failure in Japan, we determined that patients without cirrhosis at baseline should be excluded from the disease entity of ACLF in Japan.
Should patients with decompensated cirrhosis as well as those with compensated cirrhosis at baseline be included in the disease entity of ACLF?
Among patients with cirrhosis, those with grade A or grade B liver damage (total score of 5-9) at baseline according to the Child-Pugh classification are included in the disease entity of ACLF in Japan, whereas those with grade C liver damage (total score ≥10) are excluded. Some patients with cirrhosis and grade C liver damage may fulfill the standards for prothrombin time and/or serum bilirubin concentration defined by the diagnostic criteria for ACLF even at baseline. Patients who do not fulfill these diagnostic criteria for ACLF, despite having grade C liver disease, may subsequently come to fulfill these criteria, but this process is diagnosed as "chronic decompensation," not ACLF.
Should patients previously manifesting grade C liver damage be included in the disease entity of ACLF?
The APASL criteria specify that patients with previous decompensation should be excluded from the disease entity of ACLF. 7 The pilot survey, however, revealed that 48.2% of the enrolled patients were rescued without receiving LT, 12 suggesting that these patients may recover from the decompensation as well as from the disease entity of ACLF. In Japan, various therapeutic agents are used to treat ascites and hepatic encephalopathy, and many patients with cirrhosis experience an attenuation of their liver damage following adequate treatment. Moreover, the enforcement regulations of the Act for the Welfare of Persons with Physical Disabilities (Act No. 283 of 1949) specify that the total scores for the Child-Pugh classification should be calculated following sufficient therapeutic support for ascites, hepatic encephalopathy, and nutrition when patients with decompensated cirrhosis submit an application form for liver dysfunction. Considering these medical circumstances in Japan, patients previously manifesting grade C liver damage are not excluded from the disease entity of ACLF when the baseline liver damage has attenuated from grade C to grade A or grade B.
Should patients with hepatocellular carcinoma be included in the disease entity of ACLF?
In the pilot survey, patients with hepatocellular carcinoma (HCC) were excluded from enrollment, 12 as the progression of HCC in the liver may contribute to a deterioration in liver function. The causes of death in such patients should be classified as "malignant neoplasm," not "liver failure." In real-world practice, however, we determined that patients with cirrhosis and HCC can be diagnosed as having ACLF if a hepatologist determines that the HCC is not responsible for the deterioration in liver function.
What are the acute insults that can lead to a deterioration of liver function?
The acute insults contributing to a deterioration of liver function in patients with cirrhosis can be classified as intrahepatic and extrahepatic insults. Hepatitis exacerbation in patients with persistent HBV and HCV infections and in those with autoimmune hepatitis, superimposed infections with hepatitis viruses, drug-induced liver injuries, and alcohol abuse belong to the former category, whereas bacterial infection and gastrointestinal bleeding belong to the latter. In patients experiencing extrahepatic insults, in particular, multiple organ failure can develop frequently as a result of systemic inflammatory response syndrome. Thus, in Europe and the USA, patients with cirrhosis are diagnosed as having ACLF based on the extent of extrahepatic organ function failure as well as liver function failure according to the EASL-Clif Consortium criteria. 9 Among 109 patients who fulfilled the criteria for decompensation based on the APASL definition, the acute insults responsible for the deterioration of liver function were alcohol abuse in 50 patients (45.9%), bacterial infection including SBP in 26 patients (23.9%), an exacerbation of hepatitis because of an underlying liver disease in 14 patients (12.8%), and gastrointestinal bleeding in 7 patients (6.4%). Among these patients, the etiologies of the underlying liver diseases were alcohol abuse in 67 patients (61.5%) including 8 patients with HBV/HCV infection or PBC in addition to alcohol abuse. In contrast, in Europe and the USA, the most common acute insults were bacterial infection (32.6%), whereas alcohol abuse was responsible for a deterioration of liver function in only 24.5% of patients diagnosed as having ACLF according to the EASL-Clif Consortium criteria, despite the fact that the etiology of the underlying liver disease was alcohol abuse in 60.3% of these patients. 9 The clinical features of patients with ACLF seem to differ between Japan and Europe and North America. Although the leading etiology for cirrhosis is HCV infection in Japan, 11 ACLF may tend to develop in patients with cirrhosis caused by habitual alcohol intake following alcohol abuse as an acute insult, suggesting that severe alcoholic hepatitis 15 is the most common liver disease among the disease entity.
In contrast, in China, where HBV infection has spread nationwide, the etiology of the underlying liver disease was HBV infection in 52.5% of the patients with ACLF diagnosed according to the APASL criteria, whereas the acute insult was hepatitis exacerbation because of viral reactivation or superimposed infection in only 33.5%. 10 The most common insult was bacterial infection (58.4%), and alcohol abuse and gastrointestinal bleeding was present in 23.4% and 13.7% of the cases, respectively. 10 Although gastrointestinal bleeding is excluded from the acute insults defined by the APASL criteria in a strict sense, patients with such insults were included in the disease entity of ACLF in the Chinese survey. According to the APASL criteria, gastrointestinal bleeding occurs as a result of liver failure, but not as a causative event in liver failure, in patients with chronic liver diseases. In Japan, however, where progress has been made on endoscopic and angiographic therapies for gastrointestinal bleeding, such bleeding rarely leads to a fatal outcome because of blood loss, whereas the deterioration of liver function because of ischemic liver injury is responsible for a fatal outcome in most patients with cirrhosis. Thus, in the diagnostic criteria for ACLF in Japan, gastrointestinal bleeding was included among the acute insults contributing to liver failure.
Of note, the acute insults may be indeterminate in a small number of patients with ACLF. According to the CANONIC study, potential precipitating events of ACLF were unproved in 18 (6.1%) among 303 patients diagnosed as having ACLF according to the EASL-Clif Consortium criteria. 9 How should the duration from acute insult until the development of liver failure be determined?
